News Releases Keyword search Year None202220212020201920182017201620152014201320122011201020092008 3/10/2022 AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results 3/3/2022 AcelRx to Host Fourth Quarter and Full Year 2021 Financial Results Call and Webcast on March 10, 2022 2/1/2022 AcelRx Pharmaceuticals Announces Publication of Clinical Data on the Use of Sufentanil Sublingual Tablet during Awake Plastic Surgery Procedures 1/27/2022 AcelRx Pharmaceuticals Announces Publication of an Article Highlighting the Utility of the Sufentanil Sublingual Tablet in Pain Medicine Procedures 1/12/2022 AcelRx Pharmaceuticals Announces Publication of an Editorial by an Internationally Recognized Leader in Opioid-Sparing Surgery Highlighting the Potential Advantages of the Sufentanil Sublingual Tablet in Joint Replacement Surgery 1/10/2022 AcelRx Pharmaceuticals Announces the Closing of its Acquisition of Lowell Therapeutics First page « first Previous page ‹ previous Page 1 Current page 2 Print Page RSS Feeds
Keyword search Year None202220212020201920182017201620152014201320122011201020092008 3/10/2022 AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results 3/3/2022 AcelRx to Host Fourth Quarter and Full Year 2021 Financial Results Call and Webcast on March 10, 2022 2/1/2022 AcelRx Pharmaceuticals Announces Publication of Clinical Data on the Use of Sufentanil Sublingual Tablet during Awake Plastic Surgery Procedures 1/27/2022 AcelRx Pharmaceuticals Announces Publication of an Article Highlighting the Utility of the Sufentanil Sublingual Tablet in Pain Medicine Procedures 1/12/2022 AcelRx Pharmaceuticals Announces Publication of an Editorial by an Internationally Recognized Leader in Opioid-Sparing Surgery Highlighting the Potential Advantages of the Sufentanil Sublingual Tablet in Joint Replacement Surgery 1/10/2022 AcelRx Pharmaceuticals Announces the Closing of its Acquisition of Lowell Therapeutics First page « first Previous page ‹ previous Page 1 Current page 2
3/3/2022 AcelRx to Host Fourth Quarter and Full Year 2021 Financial Results Call and Webcast on March 10, 2022
2/1/2022 AcelRx Pharmaceuticals Announces Publication of Clinical Data on the Use of Sufentanil Sublingual Tablet during Awake Plastic Surgery Procedures
1/27/2022 AcelRx Pharmaceuticals Announces Publication of an Article Highlighting the Utility of the Sufentanil Sublingual Tablet in Pain Medicine Procedures
1/12/2022 AcelRx Pharmaceuticals Announces Publication of an Editorial by an Internationally Recognized Leader in Opioid-Sparing Surgery Highlighting the Potential Advantages of the Sufentanil Sublingual Tablet in Joint Replacement Surgery
